Portal de Periódicos da CAPES

Bevacizumab and postponed suture leakages after surgery for ulcerative colitis and rectal cancer

2007; BMJ; Volume: 56; Issue: 5 Linguagem: Inglês

10.1136/gut.2006.112524

1468-3288

A. Adenis, L. Vanseymortier, D Foissey, J F Colombel,

Angiogenesis and VEGF in Cancer

Bevacizumab is a murine-anti-human monoclonal antibody directed against vascular endothelial growth factor-A, which disrupts endothelial cell survival mechanisms, and the recruitment and development of new tumour blood supply. Bevacizumab has been shown to prolong the duration of survival of patients with metastatic colorectal cancer when combined with chemotherapy.1 Owing to its antiangiogenic properties, bevacizumab is also known to alter the healing process and to increase the rate of surgical wound healing complications, either in patients who underwent …